Literature DB >> 19067428

Effects of light smoking consumption on the clinical course of Crohn's disease.

Philippe Seksik1, Isabelle Nion-Larmurier, Harry Sokol, Laurent Beaugerie, Jacques Cosnes.   

Abstract

BACKGROUND: Cigarette smoking is associated with a more severe Crohn's disease (CD) course. However, the effect of light consumption is not known. Our aim was to characterize the effect of a light tobacco consumption on the course of CD.
METHODS: We analyzed the course of CD during the period 1995-2007 from data collected in 2795 consecutive patients in whom smoking habits were recorded. Patients were classified as nonsmokers (n = 1420), light smokers (1-10 cigarettes/day; n = 385), heavy smokers (>10 cigarettes/day; n = 638), and intermittent smokers (change in smoking habits; n = 352). Patient-years while smoking were compared to patient-years without smoking. The analyses considered patient-years regarding annual disease activity and therapeutic requirements.
RESULTS: The percentage of years with active disease was 37% in nonsmokers versus 46% in light smokers (P < 0.001; adjusted hazard ratio 1.30 [1.19-1.43]) and 48% in heavy smokers (P < 0.001; adjusted hazard ratio 1.68 [1.57-1.81]), despite an increased use of immunosuppressants in smokers. Hospitalization rates were also increased in both groups of smokers, with 12% in nonsmokers versus 15% in both groups of smokers (P < 0.001 for both comparisons). The annual rate of intestinal resection was 4.5% in nonsmokers, 5.1% in light smokers, and 5.5% in heavy smokers, with a significant difference observed between nonsmokers and heavy smokers only (P < 0.01).
CONCLUSIONS: Light smokers are doing worse than nonsmokers regarding disease activity and the need for immunosuppressants. Complete smoking cessation should be advised in all smokers with CD.

Entities:  

Mesh:

Year:  2009        PMID: 19067428     DOI: 10.1002/ibd.20828

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  27 in total

Review 1.  Management of Crohn's disease in smokers: is an alternative approach necessary?

Authors:  Pilar Nos; Eugeni Domènech
Journal:  World J Gastroenterol       Date:  2011-08-21       Impact factor: 5.742

2.  Genetic polymorphisms in metabolizing enzymes modifying the association between smoking and inflammatory bowel diseases.

Authors:  Ashwin N Ananthakrishnan; Deanna D Nguyen; Jenny Sauk; Vijay Yajnik; Ramnik J Xavier
Journal:  Inflamm Bowel Dis       Date:  2014-05       Impact factor: 5.325

Review 3.  Crohn's disease: evidence for involvement of unregulated transcytosis in disease etio-pathogenesis.

Authors:  Jay Pravda
Journal:  World J Gastroenterol       Date:  2011-03-21       Impact factor: 5.742

Review 4.  Environmental factors in the relapse and recurrence of inflammatory bowel disease: a review of the literature.

Authors:  Thomas D Martin; Simon S M Chan; Andrew R Hart
Journal:  Dig Dis Sci       Date:  2014-11-19       Impact factor: 3.199

Review 5.  Impact of environmental and dietary factors on the course of inflammatory bowel disease.

Authors:  Eduard Cabré; Eugeni Domènech
Journal:  World J Gastroenterol       Date:  2012-08-07       Impact factor: 5.742

6.  Environmental influences on the onset and clinical course of Crohn's disease-part 1: an overview of external risk factors.

Authors:  Aamir N Dam; Adam M Berg; Francis A Farraye
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-11

Review 7.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

8.  Evidence-based clinical practice guidelines for inflammatory bowel disease.

Authors:  Katsuyoshi Matsuoka; Taku Kobayashi; Fumiaki Ueno; Toshiyuki Matsui; Fumihito Hirai; Nagamu Inoue; Jun Kato; Kenji Kobayashi; Kiyonori Kobayashi; Kazutaka Koganei; Reiko Kunisaki; Satoshi Motoya; Masakazu Nagahori; Hiroshi Nakase; Fumio Omata; Masayuki Saruta; Toshiaki Watanabe; Toshiaki Tanaka; Takanori Kanai; Yoshinori Noguchi; Ken-Ichi Takahashi; Kenji Watanabe; Toshifumi Hibi; Yasuo Suzuki; Mamoru Watanabe; Kentaro Sugano; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2018-02-10       Impact factor: 7.527

9.  Mandibular trabecular bone structure in adults with Crohn's disease.

Authors:  Grethe Jonasson; Fredrik Lindberg; Alberto Jorge; Torgny Alstad; Hossein Kashani
Journal:  Clin Oral Investig       Date:  2013-04-17       Impact factor: 3.573

10.  Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn's disease.

Authors:  Peter Laszlo Lakatos; Zsofia Czegledi; Tamas Szamosi; Janos Banai; Gyula David; Ferenc Zsigmond; Tunde Pandur; Zsuzsanna Erdelyi; Orsolya Gemela; Janos Papp; Laszlo Lakatos
Journal:  World J Gastroenterol       Date:  2009-07-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.